A Phase III, Randomized, Two-armed, Parallel, Triple-blind, Active-controlled, Equivalency Clinical Trial of Efficacy and Safety Pertuzumab (CinnaGen Co.) Compared With Perjeta (Originator Pertuzumab) in Neoadjuvant Treatment of HER2+ Breast Cancer
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Pertuzumab (Primary) ; Carboplatin; Docetaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors CinnaGen
Most Recent Events
- 07 Sep 2022 Primary endpoint has been met. (Breast Pathological Complete Response (bpCR), as per Results published in the BMC Cancer
- 07 Sep 2022 Results published in the BMC Cancer
- 24 Feb 2020 Status changed from recruiting to completed.